CW Advisors LLC Acquires 110,040 Shares of Kenvue Inc. $KVUE

CW Advisors LLC grew its holdings in Kenvue Inc. (NYSE:KVUE) by 77.0% during the second quarter, Holdings Channel reports. The firm owned 252,980 shares of the company’s stock after acquiring an additional 110,040 shares during the quarter. CW Advisors LLC’s holdings in Kenvue were worth $5,295,000 at the end of the most recent quarter.

Several other large investors have also added to or reduced their stakes in the business. Evergreen Wealth Solutions LLC increased its holdings in Kenvue by 2.6% in the first quarter. Evergreen Wealth Solutions LLC now owns 16,769 shares of the company’s stock worth $402,000 after purchasing an additional 432 shares in the last quarter. AlphaCore Capital LLC increased its stake in shares of Kenvue by 9.9% in the 2nd quarter. AlphaCore Capital LLC now owns 5,287 shares of the company’s stock valued at $111,000 after acquiring an additional 476 shares in the last quarter. Empirical Finance LLC lifted its position in shares of Kenvue by 1.8% during the 2nd quarter. Empirical Finance LLC now owns 28,309 shares of the company’s stock valued at $593,000 after acquiring an additional 491 shares during the period. Everett Harris & Co. CA boosted its stake in Kenvue by 1.4% during the first quarter. Everett Harris & Co. CA now owns 36,971 shares of the company’s stock worth $887,000 after acquiring an additional 500 shares in the last quarter. Finally, Proffitt & Goodson Inc. grew its holdings in Kenvue by 8.2% in the second quarter. Proffitt & Goodson Inc. now owns 6,831 shares of the company’s stock worth $143,000 after purchasing an additional 517 shares during the period. Institutional investors and hedge funds own 97.64% of the company’s stock.

Kenvue Stock Performance

Shares of Kenvue stock opened at $16.92 on Friday. Kenvue Inc. has a 52 week low of $14.02 and a 52 week high of $25.17. The company has a quick ratio of 0.69, a current ratio of 0.98 and a debt-to-equity ratio of 0.66. The business has a 50 day moving average price of $16.09 and a 200-day moving average price of $19.36. The company has a market cap of $32.42 billion, a PE ratio of 22.56 and a beta of 0.60.

Kenvue (NYSE:KVUE) last announced its quarterly earnings results on Monday, November 3rd. The company reported $0.28 earnings per share (EPS) for the quarter, topping the consensus estimate of $0.27 by $0.01. The business had revenue of $3.76 billion during the quarter, compared to the consensus estimate of $3.83 billion. Kenvue had a return on equity of 20.02% and a net margin of 9.55%.Kenvue’s revenue was down 3.5% compared to the same quarter last year. During the same quarter in the prior year, the company posted $0.28 earnings per share. Kenvue has set its FY 2025 guidance at 1.000-1.050 EPS. Equities analysts anticipate that Kenvue Inc. will post 1.14 earnings per share for the current fiscal year.

Kenvue Dividend Announcement

The company also recently announced a quarterly dividend, which was paid on Wednesday, November 26th. Stockholders of record on Wednesday, November 12th were paid a $0.2075 dividend. The ex-dividend date was Wednesday, November 12th. This represents a $0.83 annualized dividend and a dividend yield of 4.9%. Kenvue’s dividend payout ratio is presently 110.67%.

Analyst Ratings Changes

KVUE has been the topic of several research reports. Barclays upped their price objective on shares of Kenvue from $17.00 to $18.00 and gave the company an “equal weight” rating in a report on Monday, November 10th. UBS Group decreased their target price on Kenvue from $23.00 to $17.00 and set a “neutral” rating for the company in a research report on Wednesday, October 8th. The Goldman Sachs Group cut their price target on Kenvue from $22.00 to $19.00 and set a “neutral” rating on the stock in a report on Thursday, October 2nd. Rothschild Redb upgraded Kenvue from a “hold” rating to a “strong-buy” rating in a report on Friday, September 26th. Finally, Bank of America lowered their target price on Kenvue from $25.00 to $21.00 and set a “buy” rating on the stock in a research report on Wednesday, October 8th. One equities research analyst has rated the stock with a Strong Buy rating, five have issued a Buy rating and thirteen have given a Hold rating to the company’s stock. According to MarketBeat.com, Kenvue presently has an average rating of “Hold” and a consensus price target of $20.23.

Kenvue Profile

Kenvue Inc operates as a consumer health company worldwide. The company operates through three segments: Self Care, Skin Health and Beauty, and Essential Health. The Self Care segment offers cough, cold and allergy, pain care, digestive health, smoking cessation, eye care, and other products under the Tylenol, Motrin, Benadryl, Nicorette, Zarbee's, ORSLTM, Rhinocort, Calpol, and Zyrtec brands.